Human studies in the development of human immunodeficiency virus vaccines.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Infectious Diseases

• Publication date

  1995-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/INFDIS/172.5.1175PMID 7594651
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase I/II Preventive Vaccine Trials: Conference Summary

  1995cited by this paper
• Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques.

  1995cited by this paper
• Neutralizing Antibodies to HIV-1 in Seronegative Volunteers Immunized With Recombinant gp 120 From the MN Strain of HIV-1

  1994cited by this paper
• HIV Vaccine Development: A Progress Report

  1994cited by this paper
• Measuring Vaccine-Induced HIV Neutralization: Report of a Workshop

  1994cited by this paper
• Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Safety profile of HIV vaccination: first 1000 volunteers of AIDS vaccine evaluation group. NIAID AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Studies of High Doses of a Human Immunodeficiency Virus Type 1 Recombinant Glycoprotein 160 Candidate Vaccine in HIV Type 1-Seronegative Humans

  1994influential reference
• Interpreting HIV Serodiagnostic Test Results in the 1990s: Social Risks of HIV Vaccine Studies in Uninfected Volunteers

  1994cited by this paper
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.

  1994cited by this paper
• Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Vaccines against human immunodeficiency virus--progress and prospects.

  1993cited by this paper
• Heterologous protection against influenza by injection of DNA encoding a viral protein.

  1993cited by this paper
• Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.

  1993cited by this paper
• Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.

  1993cited by this paper
• Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine.

  1993cited by this paper
• Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

  1993cited by this paper
• Human trials of experimental AIDS vaccines.

  1993cited by this paper
• The immunopathogenesis of human immunodeficiency virus infection.

  1993cited by this paper
• Human immunodeficiency virus vaccines.

  1993cited by this paper
• Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines.

  1993cited by this paper
• Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines.

  1993cited by this paper
• Primate models for HIV vaccines.

  1993influential reference
• Safety and Immunogenicity of a Fully Glycosylated Recombinant gp160 Human Immunodeficiency Virus Type 1 Vaccine in Subjects at Low Risk of Infection

  1993cited by this paper
• Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

  1993cited by this paper
• Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network.

  1992cited by this paper
• Comparative clonal analysis of human immunodeficiency virus type 1 (HIV- 1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines

  1992cited by this paper
• Highly Attenuated Poxvirus Vectors

  1992cited by this paper
• Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

  1992cited by this paper
• Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

  1992cited by this paper
• Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant GP160. The NIAID AIDS Vaccine Clinical Trials Network.

  1992cited by this paper
• Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.

  1991influential reference
• Anti-cell antibody in macaques

  1991cited by this paper
• Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen.

  1991cited by this paper
• Humoral and cell-mediated immune responses to live recombinant BCG–HIV vaccines

  1991cited by this paper
• The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

  1991cited by this paper
• Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody

  1991cited by this paper
• New use of BCG for recombinant vaccines

  1991cited by this paper
• Absence of a clinical correlation for complement‐mediated, infection‐enhancing antibodies in plasma or sera from HIV‐1-infected individuals

  1991cited by this paper
• The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans

  1991cited by this paper
• Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

  1991cited by this paper
• Antigen chimeras of poliovirus.

  1991cited by this paper
• The molecular biology of human immunodeficiency virus type 1 infection.

  1991cited by this paper
• Efficacy of SIV/deltaB670 glycoprotein-enriched and glycoprotein-depleted subunit vaccines in protecting against infection and disease in rhesus monkeys.

  1991cited by this paper
• Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients.

  1991cited by this paper
• Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody

  1991cited by this paper
• Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.

  1990cited by this paper
• Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine

  1990cited by this paper
• Vaccination Against SIV Infection and Disease

  1990cited by this paper
• A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization

  1990cited by this paper
• Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies.

  1990cited by this paper
• Animal models for AIDS.

  1990cited by this paper
• Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1

  1990cited by this paper
• High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants.

  1990cited by this paper
• Induction of CD4+ human cytolytic T cells specific for HIV-infected cells by a gp160 subunit vaccine.

  1990cited by this paper
• Antigenic variation in HIV.

  1990cited by this paper
• Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

  1990cited by this paper
• Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding

  1990cited by this paper
• Pathogenesis of Human Immunodeficiency Virus Infection

  1989cited by this paper
• A formalin-inactivated whole SIV vaccine confers protection in macaques.

  1989cited by this paper
• An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies

  1989cited by this paper
• Vaccine protection against simian immunodeficiency virus infection.

  1989cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Monoclonal Antibodies to HTLV-III451 gp41: Delineation of an Immunoreactive Conserved Epitope in the Transmembrane Region of Divergent Isolates of HIV-1

  1989cited by this paper
• Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

  1988cited by this paper
• Simian immunodeficiency viruses.

  1988cited by this paper
• Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides.

  1988cited by this paper
• The expression of hybrid HIV:Ty virus-like particles in yeast

  1987cited by this paper
• Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein.

  1986cited by this paper
• Expression of AIDS virus envelope gene in recombinant vaccinia viruses

  1986cited by this paper
• TRANSMISSION EXPERIMENTS WITH HUMAN T-LYMPHOTROPIC RETROVIRUSES AND HUMAN AIDS TISSUE

  1984cited by this paper
• Transmission of HTLV-III infection from human plasma to chimpanzees: an animal model for AIDS.

  1984cited by this paper
• INFECTION OF CHIMPANZEES WITH LYMPHADENOPATHY-ASSOCIATED VIRUS

  1984cited by this paper
• Animal models of AIDS.

  1984cited by this paper

• HIV Vaccine

  2018cites this paper
• Infections in Children.

  2018cites this paper
• Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome

  2009cites this paper
• Immunotherapy with Canarypox Vaccine and Interleukin-2 for HIV-1 Infection: Termination of a Randomized Trial

  2007cites this paper
• Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: Clinical Testing Challenges

  2006cites this paper
• Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif

  2006cites this paper
• Human Immunodeficiency Virus: Scientific Challenges Impeding Candidate Vaccines

  2003cites this paper
• Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

  2003cites this paper
• Preformulation study of the vaccine candidate TAB9 against HIV‐1

  2002cites this paper
• HIV-1 vaccines: the search continues.

  2002cites this paper
• HIV-1 Vaccine Testing, Trial Design, and Ethics

  2002cites this paper
• Host Determinants in HIV Infection and Disease: Part 2: Genetic Factors and Implications for Antiretroviral Therapeutics*

  2001cites this paper
• Challenges and opportunities for development of an AIDS vaccine

  2001cites this paper
• A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers.

  2001cites this paper
• HIV vaccines for prevention of infection and disease in humans.

  2000cites this paper
• Vaccinia reactive antibodies in a south Indian population

  2000cites this paper
• Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1.

  2000cites this paper
• Assessment of HIV vaccine development: past, present, and future.

  2000cites this paper
• Hsp70 in immunotherapy : a potential vector in cancer and viral vaccines

  2000cites this paper
• Designing a Vaccine Against HIV

  1999cites this paper
• Human trials of HIV-1 vaccines.

  1999cites this paper
• Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases.

  1999cites this paper
• Booster immunization of HIV-1 negative volunteers with HGP-30 vaccine induces protection against HIV-1 virus challenge in SCID mice.

  1999cites this paper
• A prime-boost regime that combines Montanide ISA720 and Alhydrogel to induce antibodies against the HIV-1 derived multiepitope polypeptide TAB9.

  1999cites this paper
• Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infectees.

  1999cites this paper
• Role of Immune Responses against the Envelope and the Core Antigens of Simian Immunodeficiency Virus SIVmne in Protection against Homologous Cloned and Uncloned Virus Challenge in Macaques

  1999cites this paper
• Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial. European Multinational IMMUNO AIDS Vaccine Study Group.

  1999cites this paper
• Modulation of HIV immune responses in natural infection and after genetic immunization

  1999cites this paper
• Infections in children. Proceedings of the 4th Liverpool School of Tropical Medicine and Bayer Symposium on Microbial Disease.

  1998cites this paper
• Acquired Immunodeficiency Syndrome Vaccines: Current Concepts and Future Prospects

  1998cites this paper
• Symposium in Immunology VII

  1998cites this paper
• Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.

  1998cites this paper
• Validation and Standardization of Serologic Methods for Evaluation of Clinical Immune Response to Vaccines

  1998cites this paper
• Cytotoxic T Cell and Neutralizing Antibody Responses to Human Immunodeficiency Virus Type 1 Envelope with a Combination Vaccine Regimen

  1998cites this paper
• Studies of the Neutralizing Activity and Avidity of Anti-Human Immunodeficiency Virus Type 1 Env Antibody Elicited by DNA Priming and Protein Boosting

  1998cites this paper
• [Perspectives for the development of preventive vaccines against HIV/AIDS].

  1998cites this paper
• A Comprehensive Panel of Near-Full-Length Clones and Reference Sequences for Non-Subtype B Isolates of Human Immunodeficiency Virus Type 1

  1998cites this paper
• Edinburgh Research Explorer A comprehensive panel of near-full-length clones and reference sequences for non-subtype B isolates of human immunodeficiency virus type 1

  1998cites this paper
• Intermediate-size trials for the evaluation of HIV vaccine candidates: a workshop summary.

  1997cites this paper
• [Search for a HIV vaccine].

  1997cites this paper
• Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group

  1997cites this paper
• Role of immunity in maternal—infant HIV‐1 transmission

  1997cites this paper
• Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development

  1997cites this paper
• Human Immunodeficiency Virus Protease Inhibitors

  1997cites this paper
• The Enhanced Immune Response to the HIV gp160/LAMP Chimeric Gene Product Targeted to the Lysosome Membrane Protein Trafficking Pathway*

  1997cites this paper
• HIV/AIDS Vaccine Development: Challenges, Progress and Future Directions

  1996cites this paper
• Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160.

  1996cites this paper
• Human immunodeficiency viruses.

  1996cites this paper